Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (208)	4/12/2002 3:14:59 PM
From: rkrw	Read Replies (1) \| Respond to of 508

ITMN is co-developing this with molichem. No mention of itmn in the pr. Thursday April 11, 4:01 pm Eastern Time Press Release SOURCE: MoliChem Medicines, Inc. MoliChem Announces the Completion of a Phase IB Safety Study In Cystic Fibrosis Participants CHAPEL HILL, N.C., April 11 /PRNewswire-FirstCall/ -- MoliChem Medicines Inc. (OTC Bulletin Board: MLCM - news) announced today the completion of a Phase IB safety study of its lead product candidate, Moli1901, in 16 cystic fibrosis (CF) patients. CF is characterized by the chronic formation of mucus plugs in a patient's airways, caused by abnormal chloride and water transport. Moli1901 may normalize the mucus composition in the lung by activating an alternative chloride channel that is present in the airway epithelia of CF patients. An initial study in CF patients found Moli1901 to be safe and well tolerated in nasal epithelium exposed to the drug. This Phase IB study, conducted at Children's Hospital Boston, Children's Hospital Columbus, and John Hopkins Children's Hospital, further supports the safety of Moli1901 administered by inhalation in CF patients with single doses in aerosol up to 2.5 mg. No significant airway irritation nor serious adverse events were reported in this study. ``These data will support additional studies to characterize the residence time of the drug in the lung and the duration of action of Moli1901 in the CF lung,'' said Luis Molina, Ph.D. President/CEO of MoliChem. ``The successful completion of this clinical trial in CF patients is an important milestone as we progress to Phase II studies.'' About MoliChem MoliChem Medicines, Inc. is an early stage pharmaceutical company focused on the discovery, development, and marketing of products for the treatment of serious respiratory and related conditions. MoliChem's lead product, Moli1901, is currently in clinical trials in the United States for the treatment of cystic fibrosis. The company also has two free radical scavengers in pre-clinical development, including Moli56A and Moli56B, which are being evaluated as therapy to prevent toxic injuries to major organ systems. Additionally, MoliChem has a platform for discovery of stable polypeptides with a lead compound that has demonstrated activity against multiple drug resistant tuberculosis strains.